12 min · 12 chaptersNarrated in your voice
What it's about
John Carreyrou, the Wall Street Journal reporter who broke the story, documents how Theranos, a blood-testing startup once valued at $9 billion, was built on technology that never worked. The book traces founder Elizabeth Holmes's decade-long deception of investors, partners, regulators, and patients, and argues that Silicon Valley's tolerance for grand claims without proof let a dangerous fraud in medicine go unchecked far longer than it should have.
Reading plan
Pick a finish date and Genius lays out the days — the plan shows today's target and keeps you honest.
Read together
Start a circle and share the code — everyone sees everyone's honest place in the book. Accountability, not leaderboards.
Who it's for
- Investors and board members who want to see how due diligence fails when charisma substitutes for evidence. - Healthcare and biotech professionals who need a case study in what happens when lab science is subordinated to marketing. - General readers drawn to corporate scandal stories who want the full mechanics of a decade-long fraud, not just headlines.
What’s inside
- 1A Founder's Origin Myth1 min
Elizabeth Holmes built Theranos around a narrative of world-changing intention rather than proven technology, and for over a decade that story substituted for evidence.
- 2Building an Illusion of Technology1 min
Theranos's proprietary device never worked reliably, and the company concealed this by secretly running most patient tests on modified commercial machines while telling the public its own technology performed the analysis.
- 3Cult of Personality and Secrecy1 min
Holmes and her partner Sunny Balwani ran Theranos through deliberate compartmentalization and fear, and this internal opacity is what let the gap between claim and reality survive for years without being widely known.
- 4Borrowed Credibility: The Board1 min
Theranos recruited statesmen and retired generals rather than scientists or clinicians to its board, and this created an appearance of rigor that substituted for genuine technical oversight.
- 5Faking It for Partners and Investors1 min
Theranos secured its most consequential business partnerships by staging demonstrations that misrepresented the state of its technology, showing that sophisticated corporate partners can be deceived as easily as individual investors.
- 6The Human Cost: Employees Who Spoke Up1 min
Internal whistleblowers, not outside regulators, delivered the first credible challenge to the fraud, and they paid heavily for it before anyone believed them.
- 7Weaponizing the Law1 min
Theranos used its attorney David Boies and the threat of ruinous litigation to silence critics, revealing that legal intimidation, not scientific rebuttal, was the company's primary defense against exposure.
- 8The Reporter Who Wouldn't Back Down1 min
Carreyrou's investigation succeeded because he assembled a chain of confidential, legally vulnerable sources willing to risk lawsuits, proving that patient, source-based journalism can crack even a heavily lawyered operation.
- 9Collapse1 min
Once regulators and former partners examined Theranos's actual lab results rather than its public claims, the company's value evaporated within about two years, showing how quickly a valuation built on unverified marketing can disappear.
About John Carreyrou
John Carreyrou is an investigative reporter who spent nearly two decades at the Wall Street Journal, winning two Pulitzer Prizes before his Theranos coverage. His 2015 articles exposing the company's failing technology, built from confidential sources inside the company, formed the basis of this book.
